Mirum Pharmaceuticals, Inc. 4

CEO Christopher Peetz exercised 20,000 Mirum Pharmaceuticals (MIRM) stock options at $2.936 and sold 20,000 common shares in multiple open-market transactions around $122–$125 on July 6, 2026 under a Rule 10b5-1 plan.

On July 6, 2026, Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised 20,000 stock options at an exercise price of $2.936 per share, acquiring 20,000 shares of common stock, and on the same day sold a total of 20,000 shares in four open-market transactions at weighted average prices ranging from $121.65 to $124.79 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026. The gross value of the sales was approximately $2.45 million versus an option exercise cost of about $59,000, implying a substantial realized spread, while his direct holdings decreased modestly and, together with indirect trust holdings, remain substantial. The underlying employee stock option is fully vested and, after these transactions, Peetz held 194,309 shares of common stock directly and 187,500 shares indirectly through The Peetz Family Trust, plus 108,487 shares underlying outstanding options, leaving him with significant ongoing equity exposure to Mirum.

Filing Facts

CIK

1759425

Ticker

MIRM

Form

4

Source Type

fda

Accession

0001614740-26-000011

Alert Tier

7